Health
A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity – News-Medical.Net
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome…
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
New approaches to spike-based vaccines
Both the viral spike antigen and its receptor-binding domain (RBD), which elicit highly potent neutralizing…
-
Noosa News7 hours agoHow Lily Steele-Park took her rapist to court and won
-
General21 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business11 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General23 hours agoFears for next anti-Semitic firebombing on home soil